Edinburgh Molecular Imaging company

Edinburgh Molecular Imaging, a Scottish (UK) developer of systemic radiotherapy with cross cancer potential targeting c-Met, was founded in 2014. Originally EMI developed fluorescent optical imaging agents (EMI-137) for detection and surgical guidance of cancer. EMI-137 has passed successfully stage 2b in CRC. In 2019 the company transformed itself into therapeutics, using its c-Mat targeting platform to develop a systemic radiotheragnostic pair [Ga68]EMP-10X / [Lu177/Ac225]EMP-10X. PoC in 16 patiens has been achieved and clinical development has started. The EM Imaging team has decades of documented success in imaging agent discovery and development with expertise spanning medicinal chemistry, biochemistry and cell biology, along with direct clinical expertise. The team has expertise in the clinical development, FDA, EMA approvals, US and EU reimbursement, and broad commercialization in US and EU.

Investors

Total Funding: £7.1M
Headquarters: Edinburgh, Edinburgh, City of, United Kingdom
Funding Status: Early Stage Venture
Employee Number: 1-10
Investment Stage: N/A
Last Funding Type: Venture - Series Unknown
Number Of Exists: Venture - Series Unknown
Technology: Regenerative Medicine
Investor Type: Company
Investors Number: 4
Founded Date: 2014
Industry: Personalized Medicine
Register and Claim Ownership